Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Adults With Diabetes in High-Deductible Health Plans More Likely to Have Severe Hyperglycemia
January 26th 2023Adults with diabetes who were forced to switch from an employer-sponsored health plan to a high-deductible health plan (HDHP) were 25% more likely to require an emergency department (ED) or hospital visit for hyperglycemia, but not for hypoglycemia, than those who did not switch plans.
Read More
Fetal Outcomes, Maternal Mortality Vary Among Pregnant Women With Different Types of PH
January 19th 2023A small study conducted in China suggests pregnant women with idiopathic pulmonary arterial hypertension (iPAH) are at higher risk of maternal mortality compared with women with certain other types of pulmonary hypertension (PH).
Read More
Social Determinants of Health Linked With Varying Prostate Cancer Outcomes by Race
January 13th 2023A meta-analysis supported that Black men have similar or better prostate cancer outcomes compared with White men when health care access is equal and treatment is standardized for all patients.
Read More
In Pediatric Epilepsy, Links Found Between Parental Factors, Emotional and Behavioral Issues
January 10th 2023A study showed 18.3% of adolescents with epilepsy (AWE) had at least 1 emotional or behavioral problem, and 24.9% of parents felt others had stigma towards their children with epilepsy.
Read More
Age Considerations for Findings on Venetoclax Combined With CLIA for AML, High-Risk MDS
December 29th 2022Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, explains the implications of the longer-term follow-up of venetoclax in combination with the chemotherapy regimen cladribine, high-dose cytarabine, idarubicin (CLIA) and how age is a factor when considering chemotherapy options.
Read More
Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC
December 21st 2022Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Read More
T1D Community Helped Create T1D Index, Says JDRF's Tom Robinson
December 17th 2022Tom Robinson, vice president of global access at JDRF, talks about how the community and people living with type 1 diabetes (T1D) have contributed to the T1D Index, from development to publication and going forward.
Read More
Dr Patrick Reville Covers Study Results on Venetoclax Combined With CLIA
December 16th 2022Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, discusses findings on an updated treatment regimen for newly-diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Read More
How Ochsner, Xavier Are Working Together to Make Louisiana a Healthy State
December 15th 2022Leaders from Ochsner, Xavier, and their partners gathered on September 13, 2022, in New Orleans to offer an overview of the Healthy State initiative during a session of the Institute for Value-Based Medicine®.
Read More
Conversations Around HIV PrEP With Adolescents Vary Between Urban, Rural Family Physicians
December 15th 2022This new study shows that family medicine physicians in rural areas tend to be less comfortable in HIV pre-exposure prophylaxis (PrEP)-related clinical activities and conversations with adolescents than those in urban areas.
Read More
Dr Mary Cushman: Disparities in Pulmonary Embolism Exist; We Need to Ask Why
December 14th 2022Health care providers must acknowledge unconscious bias and watch for it to make sure treatments are given equitably, said Mary Cushman, MD, professor of medicine at the University of Vermont, director of the thrombosis and hemostasis program at the University of Vermont Medical Center.
Read More
TRANSFORM Data Support Liso-cel as Second-line Treatment for LBCL, Says Dr Jeremy Abramson
December 13th 2022The longer follow-up in the primary analysis of TRANSFORM provides confidence in the durability of patient responses to lisocabtagene maraleucel (liso-cel), said Jeremy Abramson, MD, director of the lymphoma program, Massachusetts General Hospital Cancer Center.
Read More
Dr Ajai Chari Talks Phase 1 Results of Bispecific Antibody Talquetamab for Multiple Myeloma
December 13th 2022Ajai Chari, MD, professor of medicine, director of clinical research, Icahn School of Medicine at Mount Sinai, explains the mechanism of action of talquetamab and what method of delivery patients may prefer.
Read More
Dr Elias Jabbour: Third-line Ponatinib “Optimal” for Patients With CML-CP Without T3151 Mutation
December 12th 2022Third-line ponatinib is the optimal treatment option for patients with chronic myeloid leukemia in chronic phase (CML-CP) without T3151 mutation, said Elias Jabbour, MD, professor of medicine, Department of Leukemia, MD Anderson Cancer Center.
Read More
Breakthrough COVID-19 Infection in 10% of Patients With Blood Cancer, LLS Data Show
December 12th 2022About 10% of patients with blood cancer, especially those with B-cell lymphomas, who did not make anti-spike antibodies after vaccination experienced breakthrough COVID-19 infection, said Lee Greenberger, PhD, chief scientific officer, Leukemia and Lymphoma Society.
Read More